```
  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 23:11:05 ON 30 OCT 2002

=> fil reg

=> s amino and octylphenyl and ethyl
       3876237 AMINO
          8695 AMINOS
       3876237 AMINO
                 (AMINO OR AMINOS)
          4523 OCTYLPHENYL
       5141846 ETHYL
            12 ETHYLS
       5141846 ETHYL
                 (ETHYL OR ETHYLS)
L1          176 AMINO AND OCTYLPHENYL AND ETHYL

=> s propane and l1
        480981 PROPANE
L2          18 PROPANE AND L1

=> d scan

L2    18 ANSWERS   REGISTRY  COPYRIGHT 2002 ACS
IN    1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-, hydrochloride
      (9CI)
MF    C19 H33 N O2 . Cl H
```



\# HCl

```
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)17

L2    18 ANSWERS   REGISTRY  COPYRIGHT 2002 ACS
IN    Propanedioic acid, amino[3-(methyloctylphenylsilyl)propyl]-, diethyl
      ester (9CI)
MF    C25 H43 N O4 Si
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2    18 ANSWERS   REGISTRY  COPYRIGHT 2002 ACS
IN    1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-, mono(dihydrogen
      phosphate) (ester), (2R)- (9CI)
MF    C19 H34 N O5 P

Absolute stereochemistry.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 18 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN **Propanedioic acid, (acetylamino)[2-(2-octylphenyl)ethyl]-, diethyl ester (9CI)**
MF C25 H39 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 18 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN **1,3-Propanediol, 2-amino-2-[2-(3-octylphenyl)ethyl]-, hydrochloride (9CI)**
MF C19 H33 N O2 . Cl H



HCl

L2 18 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN **1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-, mono(dihydrogen phosphate) (ester) (9CI)**
MF C19 H34 N O5 P



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 18 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN **Propanedioic acid, [[(4-cyclooctylphenyl)amino]methylene]-, diethyl ester (9CI)**
MF C22 H31 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 18 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN **1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]- (9CI)**
MF C19 H33 N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 18 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN **Propanedioic acid, (acetylamino)[2-(4-octylphenyl)ethyl]-, diethyl ester, hydrochloride (9CI)**
MF C25 H39 N O5 . Cl H



HCl

L2 18 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN **1,3-Propanediol, 2-(dimethylamino)-2-[2-(4-octylphenyl)ethyl]-, mono(dihydrogen phosphate) (ester) (9CI)**
MF C21 H38 N O5 P



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 18 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN **Propanedioic acid, amino[2-(4-octylphenyl)ethyl]-, diethyl ester (9CI)**
MF C23 H37 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 18 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN **1,3-Propanediol, 2-amino-2-[2-(2-octylphenyl)ethyl]-, hydrochloride (9CI)**
MF C19 H33 N O2 . Cl H



HCl

L2 18 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN **Propanedioic acid, (acetylamino)[2-(4-octylphenyl)-2-oxoethyl]-, diethyl ester (9CI)**
MF C25 H37 N O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 18 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN **1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-, mono(dihydrogen**

phosphate) (ester), (2S)- (9CI)
MF C19 H34 N O5 P

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 18 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN **1,3-Propanediol, 2-amino-2-[2-(3-octylphenyl)ethyl]- (9CI)**
MF C19 H33 N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 18 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN **1,3-Propanediol, 2-(methylamino)-2-[2-(4-octylphenyl)ethyl]- (9CI)**
MF C20 H35 N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 18 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN **1,3-Propanediol, 2-(methylamino)-2-[2-(4-octylphenyl)ethyl]-, mono(dihydrogen phosphate) (ester) (9CI)**
MF C20 H36 N O5 P



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 18 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN **Propanedioic acid, (acetylamino)[2-(4-octylphenyl)ethyl]-, diethyl ester (9CI)**
MF C25 H39 N O5
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l2 and C19 H33 N O2/mf
302 C19 H33 N O2/MF
L3 2 L2 AND C19 H33 N O2/MF

=> d tot

L3 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2002 ACS
RN 162359-55-9 REGISTRY
CN **1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]- (9CI)** (CA INDEX NAME)
FS 3D CONCORD
MF **C19 H33 N O2**
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, DRUGUPDATES, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

15 REFERENCES IN FILE CA (1962 TO DATE)
16 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2002 ACS
RN 162359-24-2 REGISTRY
CN **1,3-Propanediol, 2-amino-2-[2-(3-octylphenyl)ethyl]- (9CI)** (CA INDEX NAME)
FS 3D CONCORD
MF **C19 H33 N O2**
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

```
=> s 162359-55-9 /rn or 162359-55-9 /crn
             1 162359-55-9 /RN
             1 162359-55-9 /CRN
L4           2 162359-55-9 /RN OR 162359-55-9 /CRN

=> d tot

L4   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2002 ACS
RN   162359-56-0  REGISTRY
CN   1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-, hydrochloride (9CI)
     (CA INDEX NAME)
OTHER NAMES:
CN   FTY 720
MF   C19 H33 N O2 . Cl H
SR   CA
LC   STN Files:   ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CA, CANCERLIT,
       CAPLUS, CASREACT, DRUGNL, DRUGUPDATES, EMBASE, IPA, MEDLINE, PHAR,
       PROMT, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
CRN  (162359-55-9)
```



\# HCl

146 REFERENCES IN FILE CA (1962 TO DATE)
146 REFERENCES IN FILE CAPLUS (1962 TO DATE)

```
L4   ANSWER 2 OF 2  REGISTRY  COPYRIGHT 2002 ACS
RN   162359-55-9  REGISTRY
CN   1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]- (9CI)  (CA INDEX
     NAME)
FS   3D CONCORD
MF   C19 H33 N O2
CI   COM
SR   CA
LC   STN Files:   CA, CAPLUS, CASREACT, DRUGUPDATES, USPAT2, USPATFULL
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

15 REFERENCES IN FILE CA (1962 TO DATE)
16 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> fil medl capl biosis uspatfull

=> s l4
L5 439 L4

=> s FTY 720
L6 196 FTY 720

=> s l5 or l6
L7 448 L5 OR L6

=> s viral or antiviral or virus? or antiviru?
L8 1484192 VIRAL OR ANTIVIRAL OR VIRUS? OR ANTIVIRU?

=> s l7 and l8
L9 21 L7 AND L8

=> dup rem l9
PROCESSING COMPLETED FOR L9
L10 17 DUP REM L9 (4 DUPLICATES REMOVED)

=> d ibib abs tot

L10 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1
Full Text
ACCESSION NUMBER: 2002:487906 CAPLUS
DOCUMENT NUMBER: 137:68163
TITLE: Delivery of therapeutic agents
INVENTOR(S): Sirhan, Motasim; Yan, John
PATENT ASSIGNEE(S): Avantec Vascular Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 49 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002082679	A1	20020627	US 2001-2595	20011101
US 2002114823	A1	20020822	US 2001-782927	20010213
US 6471980	B2	20021029		

PRIORITY APPLN. INFO.:
US 2000-258024P P 20001222
US 2001-782804 A 20010213
US 2001-782927 A 20010213
US 2001-783253 A 20010213
US 2001-783254 A 20010213
US 2001-308381P P 20010726

AB A device and a method using the device for reducing restenosis and hyperplasia after intravascular intervention are disclosed. The present invention also provides luminal prostheses which allow for controlled release of at least one therapeutic agent with increased efficacy to selected locations within a patient vasculature to reduce restenosis. An intraluminal prosthesis may comprise an expandable structure and a source adjacent the expandable structure for releasing the therapeutic capable agent into the body lumen to reduce smooth muscle cell proliferation. A therapeutic agent, mycophenolic acid, was prepd. by dissolving it in acetone at 15 mg/mL. The amt. of the drug agent varied in the range 0.1 μg-2 mg, preferably, at 600 μg. The drug soln. was then coated onto or over a stent by spraying them with an atomizer sprayer, while the stent was rotated. The stent was allowed to let dry. The stent was then placed over the tri-fold balloon on a catheter and crimped thereon. After crimping, the drug remained intact and attached to the stent. Expansion of the stent against a simulated Tecoflex vessel showed no cracking of the drug.

L10 ANSWER 2 OF 17 USPATFULL
Full Text
ACCESSION NUMBER: 2002:213450 USPATFULL

TITLE: Intravascular delivery of mycophenolic acid
INVENTOR(S): Sirhan, Motasim, Sunnyvale, CA, UNITED STATES
Yan, John, Los Gatos, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002114823	A1	20020822
	US 6471980	B2	20021029
APPLICATION INFO.:	US 2001-782927	A1	20010213 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-258024P	20001222 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1135
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides improved devices and methods for minimizing and/or inhibiting restenosis and hyperplasia after intravascular intervention. In particular, the present invention provides luminal prostheses which allow for programmed and controlled mycophenolic acid delivery with increased efficacy to selected locations within a patient's vasculature to inhibit restenosis. An intraluminal delivery prosthesis may comprise an expansible structure and means on or within the structure for releasing mycophenolic acid at a rate selected to inhibit smooth muscle cell proliferation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 17 USPATFULL
Full Text
ACCESSION NUMBER: 2002:191216 USPATFULL
TITLE: COMPOSITIONS AND METHODS OF USING COMPOSITIONS WITH ACCELERATED LYMPHOCYTE HOMING IMMUNOSUPPRESSIVE PROPERTIES
INVENTOR(S): CHIBA, KENJI, FUKUOKA, JAPAN
ADACHI, KUNITOMO, FUKUOKA, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002102279	A1	20020801
APPLICATION INFO.:	US 1999-334213	A1	19990615 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-933738, filed on 23 Sep 1997, PATENTED

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-237273	19970902

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CROWELL& MORING, INTELLECTUAL PROPERTY GROUP, P.O. BOX 14300, WASHINGTON, DC, 20044-4300
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 1432
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The methods and compositions of the invention and the compounds used in the invention involve a novel immunosuppression mechanism, accelerated lymphocyte homing immunosuppression (ALH-immunosuppression). For example, the compound FTY720 specifically directs lymphocytes to the peripheral lymph nodes, mesenteric lymph nodes, and Peyer's patches. By reversibly sequestering lymphocytes in these tissues, the compounds can inhibit an immune response in a mammal. Understanding these mechanisms provides a novel immunosuppression therapy that can synergistically interact with other immunosuppressive compounds. Screening methods for identifying similar ALH-immunosuppression compounds are also described. The invention allows better treatments and therapies wherever an immunosuppression regimen is desired.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 17 USPATFULL
Full Text
ACCESSION NUMBER: 2002:172348 USPATFULL
TITLE: Phosphate derivatives as immunoregulatory agents
INVENTOR(S): Mandala, Suzanne, Scotch Plains, NJ, UNITED STATES
Bergstrom, James, Neshanic Station, NJ, UNITED STATES
Hajdu, Richard, Old Bridge, NJ, UNITED STATES
Rosen, Hugh, Springfield, NJ, UNITED STATES
Parsons, William, Belle Mead, NJ, UNITED STATES
Card, Deborah J., Somerset, NJ, UNITED STATES
Maccoss, Malcolm, Freehold, NJ, UNITED STATES
Kathleen, Rupprecht, Cranford, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002091105	A1	20020711	
	US 6437165	B2	20020820	
APPLICATION INFO.:	US 2001-942411	A1	20010830	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-229438P	20000831 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
LINE COUNT: 1369
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Immunoregulatory compounds are disclosed of the formula: ##STR1##

and ##STR2##

as well as the pharmaceutically acceptable salts and hydrates thereof, are disclosed. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection.

Pharmaceutical compositions and methods of use are included.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 5 OF 17 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
Full Text
ACCESSION NUMBER: 2002:545604 BIOSIS
DOCUMENT NUMBER: PREV200200545604
TITLE: FTY720: Targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity.
AUTHOR(S): Brinkmann, Volker (1); Lynch, Kevin R.
CORPORATE SOURCE: (1) Novartis Pharma AG Transplantation Research, WSJ-386.101, CH-4002, Basel: volker.brinkmann@pharma.novartis.com, KRL2z@virginia.edu Switzerland
SOURCE: Current Opinion in Immunology, (October, 2002) Vol. 14, No. 5, pp. 569-575. print.
ISSN: 0952-7915.
DOCUMENT TYPE: General Review
LANGUAGE: English

L10 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2002 ACS
Full Text
ACCESSION NUMBER: 2001:31322 CAPLUS
DOCUMENT NUMBER: 134:91150
TITLE: Medicinal compositions containing 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol for preventing or treating viral myocarditis
INVENTOR(S): Matsumori, Akira
PATENT ASSIGNEE(S): Welfide Corporation, Japan
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001001978	A1	20010111	WO 2000-JP4286	20000628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001072585	A2	20010321	JP 2000-193216	20000627
EP 1201236	A1	20020502	EP 2000-940873	20000628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: JP 1999-185297 A 19990630
WO 2000-JP4286 W 20000628

AB Medicinal compns. for preventing or treating **viral** myocarditis and **viral** diseases induced by **viral** myocarditis with which cell injuries in various organs are prevented and treated regardless of **virus** type; and a method for preventing or treating. These compns. contain, as the active ingredient, 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol (I) or pharmacol. acceptable salts thereof. The above method for preventing and treating myocarditis and **viral** diseases induced by **viral** myocarditis comprises administering an ED of the above compd. or pharmacol. acceptable salts thereof. The effect of I•HCl on **viral** myocarditis in mice was examd. Also a tablet contg. I•HCl 1, lactose 90, cryst. cellulose 25, and magnesium stearate 4 mg was prepd.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 17 USPATFULL
Full Text

ACCESSION NUMBER: 2001:136691 USPATFULL
TITLE: Drug composition
INVENTOR(S): Sakai, Atsushi, Chikujo-gun, Japan
Masuda, Rumiko, Chikujo-gun, Japan
PATENT ASSIGNEE(S): Welfide Corporation, Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6277888	B1	20010821	
	WO 9837875		19980903	
APPLICATION INFO.:	US 2000-380274		20000106	(9)
	WO 1998-JP755		19980225	
			20000106	PCT 371 date
			20000106	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-43668	19970227

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Jarvis, William R. A.
ASSISTANT EXAMINER: Kim, Vickie
LEGAL REPRESENTATIVE: Crowell & Moring, L.L.P.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 541
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a pharmaceutical composition containing 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof and a lecithin, and containing a saccharide if desired, which can be formulated into a liquid preparation, and which is suitable for the suppression of rejection in organ or bone marrow transplantation, for an immunosuppressive sustention therapy or for the treatment of autoimmune diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 8 OF 17 USPATFULL

Full Text
ACCESSION NUMBER: 2001:33325 USPATFULL
TITLE: External preparation of 2-amino-2-(2-(4-octylphenyl)ethyl) propane-1,3-diol or pharmaceutically acceptable salts thereof for topical administration
INVENTOR(S): Fujii, Tsuneo, Fukuoka, Japan
Mishina, Tadashi, Fukuoka, Japan
Teshima, Koji, Saitama, Japan
Imayoshi, Tomonori, Fukuoka, Japan
PATENT ASSIGNEE(S): Welfide Corporation, Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6197829	B1	20010306
APPLICATION INFO.:	US 2000-592550		20000612 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 894728		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-342503	19951228

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Channavajjala, Lakshmi
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch, LLP
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 635
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An external preparation for topical administration which aims at inhibiting rejection reactions at organ or bone marrow transplantation or treating autoimmune diseases or allergic diseases and contains as the active ingredient 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 9 OF 17 MEDLINE DUPLICATE 2
Full Text
ACCESSION NUMBER: 2001241069 MEDLINE
DOCUMENT NUMBER: 21241644 PubMed ID: 11345389
TITLE: Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute **viral** myocarditis.
AUTHOR: Miyamoto T; Matsumori A; Hwang M W; Nishio R; Ito H; Sasayama S
CORPORATE SOURCE: Department of Cardiovascular Medicine, Kyoto University, Japan.
SOURCE: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, (2001 May) 37 (6) 1713-8.
Journal code: 8301365. ISSN: 0735-1097.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200105
ENTRY DATE: Entered STN: 20010529
Last Updated on STN: 20010529
Entered Medline: 20010521
AB OBJECTIVES: This study examines the efficacy of FTY720 (FTY), a new immunosuppressor, in the treatment of acute **viral** myocarditis in a murine model. BACKGROUND: Immunosuppressive agents have no proven therapeutic efficacy in experimental or clinical myocarditis. METHODS: Encephalomyocarditis **virus** was inoculated i.p. in DBA/2 mice on day 0. Postinoculation treatment consisted of FTY 10 mg/kg/day p.o. (FTY group), or cyclosporine A (CsA) 40 mg/kg/day p.o. (CsA group) or distilled water p.o. only (control group). Survival until day 14, as well as cardiac histopathology, **virus** concentrations, cytokines (interleukin [IL]-2, IL-12, interferon [IFN]-gamma and tumor necrosis factor [TNF]-alpha) and nitric oxide (NO) on day 5 were examined. RESULTS: In the control and CsA groups, all mice died within 10 and 7 days, respectively. However, in the FTY group, 27% of the animals survived up to day 14. Compared with the control group, 1) histological scores were significantly lower in the FTY group but unchanged in the CsA group; 2) **virus** concentration was significantly higher in the CsA group but not in the FTY group; 3)

expressions of IL-2, IL-12 and IFN-gamma in the heart were suppressed in both the FTY and CsA groups, though suppression was weaker in the FTY group; 4) TNF-alpha and NO were significantly increased in the CsA group but not in the FTY group. CONCLUSIONS: FTY720 had a significant therapeutic effect in acute experimental myocarditis without inducing excessive **virus** replication. This report is the first to describe a beneficial effect by an immunosuppressive agent in the treatment of acute **viral** myocarditis.

L10 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2002 ACS
Full Text
ACCESSION NUMBER: 2001:209277 CAPLUS
DOCUMENT NUMBER: 135:297828
TITLE: FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression
AUTHOR(S): Brinkmann, V.; Chen, S.; Feng, L.; Pinschewer, D.; Nikolova, Z.; Hof, R.
CORPORATE SOURCE: Novartis Pharma AG, Transplantation Research, Basel, Switz.
SOURCE: Transplantation Proceedings (2001), 33(1-2), 530-531
CODEN: TRPPA8; ISSN: 0041-1345
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 12 refs. The novel immunomodulator, FTY720, prolongs with remarkable potency the survival of allografted kidney, heart, liver, small bowel, and skin in animal models including nonhuman primates, and prevents the development of coronary artery disease and graft-vs.-host-disease (GVHD). It interferes with the responsiveness of lymphocytes to chemokines, suppressing lymphocyte recirculation to the periphery and infiltration of T cells into grafted organs without impairment of immune responses to systemic **viral** infection. Several expts. conducted on the efficiency of FTY720 are presented. Topics covered include modulation of chemokine-driven lymphocyte migration; impairment of T-and B-cell function; and safety pharmacol. and clin. trials.
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2002 ACS
Full Text
ACCESSION NUMBER: 2000:573775 CAPLUS
DOCUMENT NUMBER: 133:177164
TITLE: Preparation of pyrazolecarboxamides and pyrrolecarboxamides as inhibitors of the proliferation of activated lymphocytes and as remedies for autoimmune disease.
INVENTOR(S): Ushio, Hiroyuki; Ishibuchi, Seigo; Naito, Youichiro; Sugiyama, Naoki; Kawaguchi, Takafumi; Chiba, Kenji; Ohtsuki, Makio; Naka, Yoichi
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 315 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047558	A1	20000817	WO 2000-JP767	20000210
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1176140	A1	20020130	EP 2000-902925	20000210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: JP 1999-33367 A 19990210
JP 1999-198473 A 19990713
WO 2000-JP767 W 20000210

OTHER SOURCE(S): MARPAT 133:177164
GI



I



II

AB The title compds. I [R1 represents substituted aryl, heteroaryl, etc.; R2 and R3 represent each hydrogen, alkyl, halogeno, hydroxy, etc.; Q represents N, CH, etc.; W represents hydrogen, alkyl, hydroxycarbonylalkyl, etc.; X represents halogeno, cyano, nitro, amino, etc.; X' represents hydrogen, halogeno, cyano or nitro; and Y represents alkyl, hydroxy, alkoxy, etc.] are prepd. For example, pyrazolecarboxamide deriv. II was prepd. The title compds. are said to show significant inhibiting activity against the proliferation of activated lymphocytes in in vitro tests. A formulation is given.
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 12 OF 17 USPATFULL
Full Text
ACCESSION NUMBER: 2000:125105 USPATFULL
TITLE: Topical administration of 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol
INVENTOR(S): Fujii, Tsuneo, Fukuoka, Japan
Mishina, Tadashi, Fukuoka, Japan
Teshima, Koji, Saitama, Japan
Imayoshi, Tomonori, Fukuoka, Japan
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Osaka-fu, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6121329		20000919	
	WO 9724112		19970710	
APPLICATION INFO.:	US 1997-894728		19970827	(8)
	WO 1996-JP3757		19961224	
			19970827	PCT 371 date
			19970827	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-342503	19951228

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Seidleck, Brian K.
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch, LLP
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 659
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An external preparation for topical administration which aims at

inhibiting rejection reactions at organ or bone marrow transplantation or treating autoimmune diseases or allergic diseases and contains as the active ingredient 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 13 OF 17 MEDLINE DUPLICATE 3
Full Text
ACCESSION NUMBER: 2000281664 MEDLINE
DOCUMENT NUMBER: 20281664 PubMed ID: 10820254
TITLE: FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory.
AUTHOR: Pinschewer D D; Ochsenbein A F; Odermatt B; Brinkmann V; Hengartner H; Zinkernagel R M
CORPORATE SOURCE: Institute of Experimental Immunology and Laboratory for Special Techniques, Department of Pathology, University Hospital, Zurich, Switzerland.
SOURCE: JOURNAL OF IMMUNOLOGY, (2000 Jun 1) 164 (11) 5761-70. Journal code: 2985117R. ISSN: 0022-1767.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200006
ENTRY DATE: Entered STN: 20000629
Last Updated on STN: 20000629
Entered Medline: 20000621

AB FTY720 (2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol hydrochloride) prolongs survival of solid organ allografts in animal models. Mechanisms of FTY720 immunomodulation were studied in mice infected with lymphocytic choriomeningitis **virus** (LCMV) to assess T cell responses or with vesicular stomatitis **virus** to evaluate Ab responses. Oral FTY720 (0.3 mg/kg/day) did not affect LCMV replication and specific CTL and B cells were induced and expanded normally. Moreover, the anti-**viral** humoral immune responses were normal. However, FTY720 treatment showed first a shift of overall distribution of CTL from the spleen to peripheral lymph nodes and lymphocytopenia was observed. This effect was reversible within 7-21 days. Together with unimpaired T and B cell memory after FTY720 treatment, this finding rendered enhancement of lymphocyte apoptosis by FTY720 in vivo unlikely. Secondly, the delayed-type hypersensitivity reaction to a **viral** MHC class I-presented peptide was markedly reduced by FTY720. These results were supported by impaired circulation of LCMV specific TCR transgenic effector lymphocytes in the peripheral blood and reduced numbers of tissue infiltrating CTL in response to delayed-type hypersensitivity reaction. Thirdly, in a CD8+ T cell-mediated diabetes model in a transgenic mouse expressing the LCMV glycoprotein in the islets of the pancreas, FTY720 delayed or prevented disease by reducing islet-infiltrating CTL. Thus, FTY720 effectively reduced recirculation of CD8+ effector T cells and their recruitment to peripheral lesions without affecting the induction and expansion of immune responses in secondary lymphoid organs. These properties may offer the potential to treat ongoing organ-specific T cell-mediated immunopathologic disease.

L10 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2002 ACS
Full Text
ACCESSION NUMBER: 2000:896183 CAPLUS
DOCUMENT NUMBER: 135:55693
TITLE: Perioperative administration of FTY720 and CTLA4IG in rat heart transplantation
AUTHOR(S): Ohba, M.; Li, X.-K.; Kita, Y.; Tamura, A.; Enosawa, S.; Sasakuri, S.; Ogoshi, S.; Amemiya, H.; Suzuki, S.
CORPORATE SOURCE: Department of Experimental Surgery and Bioengineering, National Children's Medical Research Center, Tokyo, Japan
SOURCE: Transplantation Proceedings (2000), 32(7), 2024-2025
CODEN: TRPPA8; ISSN: 0041-1345
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A study was conducted to examine the in vitro proliferation activity of lymphocytes from recipients transfected with adenovirus vectors contg. CTLA4Ig-gene (AdCTLA4Ig) and FTY720 administered in a rat model of allogeneic heart transplantation. The administration of FTY720 or AdCTLA4Ig resulted in significant prolongation of allograft survival. The

combination therapy with FTY720 and AdCTLA4Ig caused further prolongation effects on graft survival time. The in vitro proliferation activity of lymphocytes to donor cells were completely inhibited early after grafting in both FTY720-treated recipients and AdCTLA4Ig-treated ones. FTY720-treated recipients showed a marked suppression in lymphocyte response 14 days after grafting, whereas the lymphocytes from AdCTLA4Ig-treated recipients recovered the response despite absence of a rejection episode. In addn., a remarkable inhibition of mixed lymphocyte reaction was obsd. in the lymphocytes from recipients with combination therapy.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 15 OF 17 USPATFULL
Full Text

ACCESSION NUMBER:	1999:166606 USPATFULL
TITLE:	Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties
INVENTOR(S):	Chiba, Kenji, Fukuoka, Japan Adachi, Kunitomo, Fukuoka, Japan
PATENT ASSIGNEE(S):	Yoshitomi Pharmaceutical Industries, Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6004565		19991221
APPLICATION INFO.:	US 1997-933738		19970923 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-237273	19970902

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Saunders, David
ASSISTANT EXAMINER:	Tung, Mary Beth
LEGAL REPRESENTATIVE:	Evenson, McKeown Edwards & Lenahan P.L.L.C.
NUMBER OF CLAIMS:	6
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	26 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT:	1536

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The methods and compositions of the invention and the compounds used in the invention involve a novel immunosuppression mechanism, accelerated lymphocyte homing immunosuppression (ALH-immunosuppression). For example, the compound FTY720 specifically directs lymphocytes to the peripheral lymph nodes, mesenteric lymph nodes, and Peyer's patches. By reversibly sequestering lymphocytes in these tissues, the compounds can inhibit an immune response in a mammal. Understanding these mechanisms provides a novel immunosuppression therapy that can synergistically interact with other immunosuppressive compounds. Screening methods for identifying similar ALH-immunosuppression compounds are also described. The invention allows better treatments and therapies wherever an immunosuppression regimen is desired.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 16 OF 17 USPATFULL
Full Text

ACCESSION NUMBER:	1999:106496 USPATFULL
TITLE:	Benzene compound and pharmaceutical use thereof
INVENTOR(S):	Fujita, Tetsuro, Muko, Japan Adachi, Kunitomo, Chikujo-gun, Japan Kohara, Toshiyuki, Iruma, Japan Kiuchi, Masatoshi, Iruma, Japan Chiba, Kenji, Chikujo-gun, Japan Teshima, Koji, Iruma, Japan Mishina, Tadashi, Chikujo-gun, Japan
PATENT ASSIGNEE(S):	Yoshitomi Pharmaceutical Industries, Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5948820		19990907
APPLICATION INFO.:	US 1997-801390		19970220 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 1995-JP1654, filed on 22 Aug 1995

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1994-196888	19940822
	JP 1995-82934	19950407
	JP 1995-172543	19950707

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Evenson, McKeown Edwards & Lenahan P.L.L.C.
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
LINE COUNT: 10327
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A benzene compound of the formula ##STR1## wherein each symbol is as defined in the specification; an optically active isomer or salt thereof, a medicinal composition containing the same, and an immunosuppressant containing the same as the active ingredient.

The compound, optically active isomer or salt has an excellent immunosuppressive effect and is useful as an inhibitor for the rejection reaction occurring in organ or bone marrow transplantation, and as a preventive or remedy for articular rheumatism, atopic eczema (dermatitis), Beh.cedilla.et's disease, uveal disease, systemic lupus erythematosus, Sjogren's syndrome, multiple sclerosis, myasthenia gravis, type I diabetes, endocrine ophthalmopathy, primary biliary, cirrhosis, Crohn's disease, glomerulonephritis, sarcoidosis, psoriasis, pemphigus, aplastic anemia, idiopathic thrombocytopenic purpura, allergy, polyarteritis nodosa, progressive systemic sclerosis, mixed connective-tissue disease, aortitis syndrome, polymyositis, dermatomyositis, Wegener's granuloma, ulcerative colitis, active chronic hepatitis, autoimmune hemolytic anemia, Evans' syndrome, bronchial asthma and pollinosis. It is useful also as an antifungal agent and hair growth stimulant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 17 OF 17 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
Full Text
ACCESSION NUMBER: 2000:527310 BIOSIS
DOCUMENT NUMBER: PREV200000527310
TITLE: Recurrent renal allograft rejection: Therapeutic options.
AUTHOR(S): Hauser, Ingeborg A. (1)
CORPORATE SOURCE: (1) Funktionsbereich Nephrologie, Johann Wolfgang Goethe-Universitaet, Frankfurt/Main Germany
SOURCE: Kidney & Blood Pressure Research, (1999) Vol. 22, No. 4-6, pp. 259-263. print.
Meeting Info.: Joint Scientific Meeting of the Society for Nephrology and the German Working Group for Clinical Nephrology Freiburg, Germany September 18-21, 1999
ISSN: 1420-4096.
DOCUMENT TYPE: Conference
LANGUAGE: English
SUMMARY LANGUAGE: English